220 related articles for article (PubMed ID: 34353775)
1. Genome-wide Meta-analysis Identifies Novel Genes Associated with Recurrence and Progression in Non-muscle-invasive Bladder Cancer.
Galesloot TE; Grotenhuis AJ; Kolev D; Aben KK; Bryan RT; Catto JWF; Cheng KK; Conroy S; Dyrskjøt L; Fleshner NE; James ND; Lamy P; Lindskrog SV; Malats N; Mengual L; Verhaegh G; Zeegers MP; Kiemeney LALM; Vermeulen SH
Eur Urol Oncol; 2022 Feb; 5(1):70-83. PubMed ID: 34353775
[TBL] [Abstract][Full Text] [Related]
2. Genome-wide Association Study for Tumour Stage, Grade, Size, and Age at Diagnosis of Non-muscle-invasive Bladder Cancer.
Lipunova N; Wesselius A; Cheng KK; van Schooten FJ; Bryan RT; Cazier JB; Galesloot TE; Kiemeney LALM; Zeegers MP
Eur Urol Oncol; 2019 Jul; 2(4):381-389. PubMed ID: 31277774
[TBL] [Abstract][Full Text] [Related]
3. Oncological impact of cystoscopic findings in non-muscle-invasive bladder cancer: a meta-analysis.
Yanagisawa T; Quhal F; Kawada T; Mostafaei H; Motlagh RS; Laukhtina E; Rajwa P; von Deimling M; Bianchi A; Pallauf M; Majdoub M; Pradere B; Abufaraj M; Moschini M; Karakiewicz PI; Iwatani K; Miki J; Kimura T; Shariat SF
BJU Int; 2023 Jun; 131(6):643-659. PubMed ID: 36479820
[TBL] [Abstract][Full Text] [Related]
4. Prognostic Factors for Recurrence and Progression in Korean Non-Muscle-Invasive Bladder Cancer Patients: A Retrospective, Multi-Institutional Study.
Kim HS; Ku JH; Kim SJ; Hong SJ; Hong SH; Kim HS; Kwon TG; Cho JS; Jeon SS; Joo KJ; Ahn HJ; Park HS; Seong do H; Kwon DD; Kim HJ; Lim JS; Lee HL
Yonsei Med J; 2016 Jul; 57(4):855-64. PubMed ID: 27189277
[TBL] [Abstract][Full Text] [Related]
5. Calgranulin A (S100A8) Immunostaining: A Future Candidate for Risk Assessment in Patients with Non-Muscle-Invasive Bladder Cancer (NMIBC).
Nicklas AP; Kramer MW; Serth J; Hennenlotter J; Hupe MC; Reimer DU; Stenzl A; Merseburger AS; Kuczyk MA; von Klot CJ
Adv Ther; 2018 Nov; 35(11):2054-2068. PubMed ID: 30232708
[TBL] [Abstract][Full Text] [Related]
6. Androgen Suppression Therapy Is Associated with Lower Recurrence of Non-muscle-invasive Bladder Cancer.
Wu SC; Kwon D; Jue JS; Chen FV; Velasquez Escobar MC; Punnen S; Parekh DJ; Ritch CR; Gonzalgo ML
Eur Urol Focus; 2021 Jan; 7(1):142-147. PubMed ID: 31103602
[TBL] [Abstract][Full Text] [Related]
7. Using Grade of Recurrent Tumor to Guide Further Therapy While on Bacillus Calmette-Guerin: Low-grade Recurrences Are not Benign.
Li R; Metcalfe MJ; Tabayoyong WB; Guo CC; Nogueras González GM; Navai N; Grossman HB; Dinney CP; Kamat AM
Eur Urol Oncol; 2019 May; 2(3):286-293. PubMed ID: 31200843
[TBL] [Abstract][Full Text] [Related]
8. Impact of tumor size on the oncological outcome of high-grade nonmuscle invasive bladder cancer - examining the utility of classifying Ta bladder cancer based on size.
Tully KH; Moschini M; von Rundstedt FE; Aziz A; Kluth LA; Necchi A; Rink M; Hendricksen K; Sargos P; Vetterlein MW; Seiler R; Poyet C; Krajewski W; Fajkovic H; Shariat SF; Xylinas E; Roghmann F
Urol Oncol; 2020 Nov; 38(11):851.e19-851.e25. PubMed ID: 32739227
[TBL] [Abstract][Full Text] [Related]
9. Association of De Ritis ratio with oncological outcomes in patients with non-muscle invasive bladder cancer (NMIBC).
Laukhtina E; Mostafaei H; D'Andrea D; Pradere B; Quhal F; Mori K; Miura N; Schuettfort VM; Sari Motlagh R; Aydh A; Abufaraj M; Karakiewicz PI; Enikeev D; Kimura S; Shariat SF
World J Urol; 2021 Jun; 39(6):1961-1968. PubMed ID: 32808107
[TBL] [Abstract][Full Text] [Related]
10. Genetic variability in 13q33 and 9q34 is linked to aggressiveness patterns and a higher risk of progression of non-muscle-invasive bladder cancer at the time of diagnosis.
Lenfant L; Cancel-Tassin G; Gazut S; Compérat E; Rouprêt M; Cussenot O
BJU Int; 2021 Mar; 127(3):375-383. PubMed ID: 32975901
[TBL] [Abstract][Full Text] [Related]
11. Prognostic role of pretreatment neutrophil-to-lymphocyte ratio (NLR) in patients with non-muscle-invasive bladder cancer (NMIBC): A systematic review and meta-analysis.
Vartolomei MD; Porav-Hodade D; Ferro M; Mathieu R; Abufaraj M; Foerster B; Kimura S; Shariat SF
Urol Oncol; 2018 Sep; 36(9):389-399. PubMed ID: 29884342
[TBL] [Abstract][Full Text] [Related]
12. Prognostic value of modified Glasgow Prognostic Score in non-muscle-invasive bladder cancer.
Kimura S; D' Andrea D; Soria F; Foerster B; Abufaraj M; Vartolomei MD; Iwata T; Karakiewicz PI; Rink M; Gust KM; Egawa S; Shariat SF
Urol Oncol; 2019 Mar; 37(3):179.e19-179.e28. PubMed ID: 30580906
[TBL] [Abstract][Full Text] [Related]
13. Prognostic relevance of urinary bladder cancer susceptibility loci.
Grotenhuis AJ; Dudek AM; Verhaegh GW; Witjes JA; Aben KK; van der Marel SL; Vermeulen SH; Kiemeney LA
PLoS One; 2014; 9(2):e89164. PubMed ID: 24586564
[TBL] [Abstract][Full Text] [Related]
14. Significance of Bladder Neck Involvement in Risk Substratification of Intermediate-Risk Non-muscle-invasive Bladder Cancer.
Fukushima H; Moriyama S; Waseda Y; Fukuda S; Uehara S; Tanaka H; Kijima T; Yoshida S; Yokoyama M; Ishioka J; Matsuoka Y; Saito K; Fujii Y
Eur Urol Focus; 2021 Mar; 7(2):366-372. PubMed ID: 31987764
[TBL] [Abstract][Full Text] [Related]
15. In stage pT1 non-muscle-invasive bladder cancer (NMIBC), high KRT20 and low KRT5 mRNA expression identify the luminal subtype and predict recurrence and survival.
Breyer J; Wirtz RM; Otto W; Erben P; Kriegmair MC; Stoehr R; Eckstein M; Eidt S; Denzinger S; Burger M; Hartmann A;
Virchows Arch; 2017 Mar; 470(3):267-274. PubMed ID: 28074276
[TBL] [Abstract][Full Text] [Related]
16. Ki-67 is an independent indicator in non-muscle invasive bladder cancer (NMIBC); combination of EORTC risk scores and Ki-67 expression could improve the risk stratification of NMIBC.
Ding W; Gou Y; Sun C; Xia G; Wang H; Chen Z; Tan J; Xu K; Qiang D
Urol Oncol; 2014 Jan; 32(1):42.e13-9. PubMed ID: 24360660
[TBL] [Abstract][Full Text] [Related]
17. High PDL1 mRNA expression predicts better survival of stage pT1 non-muscle-invasive bladder cancer (NMIBC) patients.
Breyer J; Wirtz RM; Otto W; Erben P; Worst TS; Stoehr R; Eckstein M; Denzinger S; Burger M; Hartmann A
Cancer Immunol Immunother; 2018 Mar; 67(3):403-412. PubMed ID: 29150702
[TBL] [Abstract][Full Text] [Related]
18. Androgen Receptor Predicts First and Multiple Recurrences in Non-Muscle Invasive Urothelial Carcinoma of the Bladder.
Yonekura S; Terauchi F; Hoshi K; Yamaguchi T; Kawai S
Pathol Oncol Res; 2019 Jul; 25(3):987-994. PubMed ID: 29862474
[TBL] [Abstract][Full Text] [Related]
19. Development and Validation of a Novel Recurrence Risk Stratification for Initial Non-muscle Invasive Bladder Cancer in Asia.
Ieda T; Muto S; Shimizu F; Taguri M; Yanada S; Kitamura K; Terai K; Saito K; Ogishima T; Nagata M; Ide H; Okegawa T; Wakumoto Y; Sakamoto Y; Tsujimura A; Yamaguchi R; Nutahara K; Horie S
EBioMedicine; 2016 Oct; 12():98-104. PubMed ID: 27614395
[TBL] [Abstract][Full Text] [Related]
20. Quantitative genome-wide methylation analysis of high-grade non-muscle invasive bladder cancer.
Kitchen MO; Bryan RT; Emes RD; Glossop JR; Luscombe C; Cheng KK; Zeegers MP; James ND; Devall AJ; Mein CA; Gommersall L; Fryer AA; Farrell WE
Epigenetics; 2016 Mar; 11(3):237-46. PubMed ID: 26929985
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]